Skip to main content
SpringerLink
Log in

Persistent and recurrent hyperparathyroidism

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

More than 95% of patients with primary hyperparathyroidism (HPT) will be cured at initial operation by an experienced surgeon. Despite this success rate, persistent and recurrent HPT remain challenging clinical entities. The most cost effective and safest treatment for persistent and recurrent HPT is avoidance by successful first operation. The contributors to treatment failure can be categorized into factors related to the initial surgical procedure, anatomic variability, and the biology of disease. An understanding of the factors that commonly contribute to treatment failure can help prevent persistent and recurrent disease and plays an integral role in planning subsequent surgical approaches. Once a biochemical diagnosis of persistent or recurrent HPT is confirmed, a thorough evaluation of previous operative, pathology, and radiology reports is essential. Localization procedures supplement this information and help direct the reoperative approach. When complementary noninvasive studies, such as ultrasound, sestamibi, and magnetic resonance imaging are negative, equivocal, or discordant, invasive tests (eg, selective venous sampling for parathyroid hormone levels) are warranted. Intraoperative ultrasound and gamma-probe localization are of questionable value, but intraoperative parathyroid hormone assays help facilitate these challenging repeat dissections. Repeat parathyroid exploration is associated with more complications and fewer cures compared to the initial explorations and should only be undertaken by an experienced surgeon in a center that can provide expert preoperative localization, adjunctive intraoperative tools, and cryopreservation of parathyroid tissue when necessary. Although controversy exists regarding indications for reoperative treatment for persistent or recurrent HPT, parathyroidectomy remains the only curative treatment option. Surgery should be considered first-line treatment in most circumstances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References and Recommended Reading

  1. Clark OH: Symposium: parathyroid disease—part 1? Contemp Surg 1998, 52:137–152.

    Google Scholar 

  2. Mundschenk J, Klose S, Lorenz K, et al.: Diagnostic strategies and surgical procedures in persistent or recurrent primary hyperparathyroidism? Exp Clin Endocrinol Diabetes 1999, 107: 331–336.

    PubMed  CAS  Google Scholar 

  3. Wadstrom C, Zedenius J, Guinea A, et al.: Re-operative surgery for recurrent or persistent primary hyperparathyroidism? Aust N Z J Surg 1998, 68:103–107.

    PubMed  CAS  Google Scholar 

  4. Al-Fehaily M, Clark OH: Persistent or recurrent primary hyperparathyroidism? Ann Ital Chir 2003, 74:423–434.

    PubMed  CAS  Google Scholar 

  5. Eigelberger MS, Cheah WK, Ituarte PH, et al.: The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg 2004, 4:528–535.

    Article  Google Scholar 

  6. Abdelhadi M, Nordenstrom J: Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism? J Clin Endocrinol Metab 1998, 83:3845–3851.

    Article  PubMed  CAS  Google Scholar 

  7. Hedback G, Tisell LE, Bengtsson BA, et al.: Premature death in patients operated on for primary hyperparathyroidism? Wor l d J Surg 1990, 14:829–835.

    Article  CAS  Google Scholar 

  8. Hedback G, Oden A: Increased risk of death from primary hyperparathyroidism: an update? Eur J Clin Invest 1998, 28:271–276.

    Article  PubMed  CAS  Google Scholar 

  9. Hedback G, Oden A: Death risk factor analysis in primary hyperparathyroidism? Eur J Clin Invest 1998, 28:1011–1118.

    Article  PubMed  CAS  Google Scholar 

  10. Palmer M, Adami HO, Bergstrom R, et al.: Survival and renal function in untreated hypercalcaemia: population-based cohort study with 14 years of follow-up? Lancet 1987, 1:59–62.

    Article  PubMed  CAS  Google Scholar 

  11. Mariette C, Pellissier L, Combemale F, et al.: Reoperation for persistent or recurrent primary hyperparathyroidism? Langenbecks Arch Surg 1998, 383:174–179.

    PubMed  CAS  Google Scholar 

  12. Wells SA Jr, Debenedetti MK, Doherty GM: Recurrent or persistent hyperparathyroidism? J Bone Miner Res 2002, 17(Suppl 2):N158—N162. A solid overview of recurrent and persistent HPT. This paper pays particular attention to the underlying causes of recurrent and persistent disease and the subsequent operative approaches.

    PubMed  Google Scholar 

  13. Tezelman S, Shen W, Siperstein AE, et al.: Persistent or recurrent hyperparathyroidism in patients with double adenomas? Surgery 1995, 118:1115–1122.

    Article  PubMed  CAS  Google Scholar 

  14. Jaskowiak N, Norton JA, Alexander HR, et al.: A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma? Ann Surg 1996, 224:308–320.

    Article  PubMed  CAS  Google Scholar 

  15. Shen W, Duren M, Morita E, et al.: Reoperation for persistent or recurrent primary hyperparathyroidism? Arch Surg 1996, 131:861–867.

    PubMed  CAS  Google Scholar 

  16. Kebebew E, Arici C, Duh QY, et al.: Localization and reoperation results for persistent and recurrent parathy-roid carcinoma? Arch Surg 2001, 136:878–885.

    Article  PubMed  CAS  Google Scholar 

  17. Alexander HR Jr, Chen CC, Shawker T, et al.: Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism? J Bone Miner Res 2002, 17(Suppl 2):N133—N140. An overview of an adjunctive test used preoperatively and intraoperatively in the surgical treatment of recurrent and persistent HPT.

    PubMed  Google Scholar 

  18. Clark OH, Kaplan EL, Thompson NW, et al.: Symposium: parathyroid disease—part 2? Contemp Surg 1998, 52:213–224.

    Google Scholar 

  19. Gasparri G, Camandona M, Abbona GC, et al.: Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies? Ann Surg 2001, 233:65–69.

    Article  PubMed  CAS  Google Scholar 

  20. Udelsman R: Primary hyperparathyroidism. In Current Surgical Therapy. Edited by Cameron JL. St. Louis: Mosby; 2001:662–667.

    Google Scholar 

  21. Hubbard JG, Sebag F, Maweja S, et al.: Primary hyperparathyroidism in men 1: how radical should surgery be? Langenbecks Arch Surg 2002, 386:553–557.

    Article  PubMed  Google Scholar 

  22. Haciyanli M, Lal G, Morita E, et al.: Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma? J Am Coll Surg 2003, 197:739–746.

    Article  PubMed  Google Scholar 

  23. Kebebew E: Parathyroid carcinoma? Curr Treat Options Oncol 2001, 2:347–354.

    PubMed  CAS  Google Scholar 

  24. Lentsch EJ, Withrow KP, Ackermann D, et al.: Parathyromatosis and recurrent hyperparathyroidism? Arch Otolaryngol Head Neck Surg 2003, 129:894–896.

    Article  PubMed  Google Scholar 

  25. Jones JJ, Brunaud L, Dowd CF, et al.: Accuracy of selective venous sampling for intact parathyroid hormone in difficult patients with recurrent or persistent hyperparathyroidism? Surgery 2002, 132:944–950.

    Article  PubMed  Google Scholar 

  26. Eigelberger MS, Clark OH: Surgical approaches to primary hyperparathyroidism? Endocrinol Metab Clin North Am 2000, 29:479–502.

    Article  PubMed  CAS  Google Scholar 

  27. Thompson GB, Grant CS, Perrier ND, et al.: Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring? Arch Surg 1999, 134:699–704.

    Article  PubMed  CAS  Google Scholar 

  28. Arici C, Cheah WK, Ituarte PH, et al.: Can localization studies be used to direct focused parathyroid operations? Surgery 2001, 129:720–729.

    Article  PubMed  CAS  Google Scholar 

  29. Miura D, Wada N, Arici C, et al.: Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? Wor l d J Sur g 2002, 26:926–930.

    Article  Google Scholar 

  30. Gotway MB, Reddy GP, Webb WR, et al.: Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism? Radiology 2001, 218:783–790.

    PubMed  CAS  Google Scholar 

  31. Cook GJ, Wong JC, Smellie WJ, et al.: [11C]Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery? Eur J Endocrinol 1998, 139:195–197.

    Article  PubMed  CAS  Google Scholar 

  32. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, et al.: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century? J Clin Endocrinol Metab 2002, 87:5353–5361.

    Article  PubMed  CAS  Google Scholar 

  33. Clark OH: How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab 2003, 88:3011–3014. A recent editorial that summarizes controversial issues in surgical treatment of HPT, while evaluating the issue of traditional four gland exploration versus focused parathyroidectomy.

    Article  PubMed  CAS  Google Scholar 

  34. Dolan J, Norton JA: Surgery for persistent and recurrent primary hyperparathyroidism. In Surgical Endocrinology. Doherty GM, Skogseid B. Philadelphia: Lippincott Williams & Wilkins; 2001:173–188.

    Google Scholar 

  35. Hedback G, Oden A, Tisell LE: The influence of surgery on the risk of death in patients with primary hyperparathyroidism? World J Surg 1991, 15:399–405.

    Article  PubMed  CAS  Google Scholar 

  36. Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Can-ada: Consensus development task force on diagnosis and management of asymptomatic primary hyperparathyroidism position paper. Endocr Pract 2003, 9:400–405.

  37. Strewler GJ: Medical approaches to primary hyperparathyroidism? Endocrinol Metab Clin North Am 2000, 29:523–539. An excellent concise overview of the medical options for treatment of HPT.

    Article  PubMed  CAS  Google Scholar 

  38. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women’s Health Initiative randomized controlled trial? JAMA 2002, 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  39. Zanchetta Jr, Bogado CE: Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism? J Bone Miner Res 2001, 16:189–190.

    Article  PubMed  CAS  Google Scholar 

  40. Quarles LD: Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues? Curr Opin Nephrol Hypertens 2003, 12:349–355.

    Article  PubMed  CAS  Google Scholar 

  41. Urena P, Frazao JM: Calcimimetic agents: review and perspectives. Kidney Int Suppl 2003:S91–S96.

  42. Shoback DM, Bilezikian JP, Turner SA, et al.: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism? J Clin Endocrinol Metab 2003, 88:5644–5649. A recent randomized double blind dose-finding study that supports the role of calcimimetics as a specific treatment of HPT. This short-term study demonstrated that oral cinacalcet safely normalized serum calcium and decreased PTH.

    Article  PubMed  CAS  Google Scholar 

  43. Cohen A, Silverberg SJ: Calcimimetics: therapeutic potential in hyperparathyroidism? Curr Opin Pharmacol 2002, 2:734–739.

    Article  PubMed  CAS  Google Scholar 

  44. Harman CR, Grant CS, Hay ID, et al.: Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism? Surgery 1998, 124:1011–1019.

    Article  PubMed  CAS  Google Scholar 

  45. Bennedbaek FN, Karstrup S, Hegedus L: Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases? Eur J Endocrinol 1997, 136:240–250.

    Article  PubMed  CAS  Google Scholar 

  46. Khafif A, Halperin D, Marshak G: Ethanol injection to parathyroid tissue: indications and limitations? Ear Nose Throat J 1998, 77:538–540.

    PubMed  CAS  Google Scholar 

  47. Heller HJ, Miller GL, Erdman WA, et al.: Angiographic ablation of mediastinal parathyroid adenomas: local experience and review of the literature? Am J Med 1994, 97:529–534.

    Article  PubMed  CAS  Google Scholar 

  48. Howell P, Kariampuzha S, Kipgen W, et al.: Non-surgical therapy of primary hyperparathyroidism? J Okla State Med Assoc 2001, 94:561–565.

    PubMed  CAS  Google Scholar 

  49. Pallotta JA, Sacks BA, Moller DE, et al.: Arteriographic ablation of cervical parathyroid adenomas? J Clin Endocrinol Metab 1989, 69:1249–1255.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of California San Francisco and UCSF Comprehensive Cancer Center at Mount Zion, 1600 Divisadero Street, Hellman Building, Room C3-47, 94143, San Francisco, CA, USA

    Orlo H. Clark MD, FACS

Authors
  1. Nadine R. Caron MD, MPH, FRCSC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cord Sturgeon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orlo H. Clark MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caron, N.R., Sturgeon, C. & Clark, O.H. Persistent and recurrent hyperparathyroidism. Curr. Treat. Options in Oncol. 5, 335–345 (2004). https://doi.org/10.1007/s11864-004-0024-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-004-0024-4

Keywords

Search

Navigation